108 related articles for article (PubMed ID: 38861912)
1. Gypenoside L inhibits hepatocellular carcinoma by targeting the SREBP2-HMGCS1 axis and enhancing immune response.
Xiao MY; Pei WJ; Li S; Li FF; Xie P; Luo HT; Hyun Yoo H; Piao XL
Bioorg Chem; 2024 Jun; 150():107539. PubMed ID: 38861912
[TBL] [Abstract][Full Text] [Related]
2. Gypenosides suppress hepatocellular carcinoma cells by blocking cholesterol biosynthesis through inhibition of MVA pathway enzyme HMGCS1.
Xiao MY; Li FF; Xie P; Qi YS; Xie JB; Pei WJ; Luo HT; Guo M; Gu YL; Piao XL
Chem Biol Interact; 2023 Sep; 383():110674. PubMed ID: 37604220
[TBL] [Abstract][Full Text] [Related]
3. Krüppel-like Factor 13 Promotes HCC Progression by Transcriptional Regulation of HMGCS1-mediated Cholesterol Synthesis.
Chen CC; Xie XM; Zhao XK; Zuo S; Li HY
J Clin Transl Hepatol; 2022 Dec; 10(6):1125-1137. PubMed ID: 36381108
[TBL] [Abstract][Full Text] [Related]
4. CSN6-SPOP-HMGCS1 Axis Promotes Hepatocellular Carcinoma Progression via YAP1 Activation.
Li K; Zhang J; Lyu H; Yang J; Wei W; Wang Y; Luo H; Zhang Y; Jiang X; Yi H; Wang M; Zhang C; Wu K; Xiao L; Wen W; Xu H; Li G; Wan Y; Yang F; Yang R; Fu X; Qin B; Zhou Z; Zhang H; Lee MH
Adv Sci (Weinh); 2024 Apr; 11(14):e2306827. PubMed ID: 38308184
[TBL] [Abstract][Full Text] [Related]
5. KIF11 manipulates SREBP2-dependent mevalonate cross talk to promote tumor progression in pancreatic ductal adenocarcinoma.
Gu X; Zhu Q; Tian G; Song W; Wang T; Wang A; Chen X; Qin S
Cancer Med; 2022 Sep; 11(17):3282-3295. PubMed ID: 35619540
[TBL] [Abstract][Full Text] [Related]
6. Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma.
Ogura S; Yoshida Y; Kurahashi T; Egawa M; Furuta K; Kiso S; Kamada Y; Hikita H; Eguchi H; Ogita H; Doki Y; Mori M; Tatsumi T; Takehara T
Oncotarget; 2018 Apr; 9(30):21022-21035. PubMed ID: 29765517
[TBL] [Abstract][Full Text] [Related]
7. Caspase-3-Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma.
Mok EHK; Leung CON; Zhou L; Lei MML; Leung HW; Tong M; Wong TL; Lau EYT; Ng IOL; Ding J; Yun JP; Yu J; Zhu HL; Lin CH; Lindholm D; Leung KS; Cybulski JD; Baker DM; Ma S; Lee TKW
Cancer Res; 2022 Sep; 82(17):3102-3115. PubMed ID: 35767704
[TBL] [Abstract][Full Text] [Related]
8. Gypenoside LI arrests the cell cycle of breast cancer in G0/G1 phase by down-regulating E2F1.
Zu ML; Duan Y; Xie JB; Qi YS; Xie P; Borjigidai A; Piao XL
J Ethnopharmacol; 2021 Jun; 273():114017. PubMed ID: 33716078
[TBL] [Abstract][Full Text] [Related]
9. Gypenoside L and Gypenoside LI Inhibit Proliferation in Renal Cell Carcinoma
Liu H; Li X; Xie J; Lv C; Lian F; Zhang S; Duan Y; Zeng Y; Piao X
Front Pharmacol; 2022; 13():820639. PubMed ID: 35370678
[TBL] [Abstract][Full Text] [Related]
10. LATS-regulated nuclear-cytoplasmic translocation of SREBP2 inhibits hepatocellular carcinoma cell migration and invasion via epithelial-mesenchymal transition.
Zhang F; Gao J; Liu X; Sun Y; Liu L; Hu B; Wang Z; Shi J; Guo W; Zhang S
Mol Carcinog; 2023 Jul; 62(7):963-974. PubMed ID: 37042569
[TBL] [Abstract][Full Text] [Related]
11. Improved Aitongxiao prescription (I-ATXP) induces apoptosis, cell cycle arrest and blocks exosomes release in hepatocellular carcinoma (HCC) cells.
Huang MB; Gao Z; Xia M; Zhao X; Fan X; Lin S; Zhang L; Huang L; Wei A; Zhou H; Wu JY; Roth WW; Bond VC; Leng J
Int J Physiol Pathophysiol Pharmacol; 2022; 14(2):90-113. PubMed ID: 35619665
[TBL] [Abstract][Full Text] [Related]
12. KLF13 suppresses the proliferation and growth of colorectal cancer cells through transcriptionally inhibiting HMGCS1-mediated cholesterol biosynthesis.
Yao W; Jiao Y; Zhou Y; Luo X
Cell Biosci; 2020; 10():76. PubMed ID: 32523679
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.
Wang ST; Ho HJ; Lin JT; Shieh JJ; Wu CY
Cell Death Dis; 2017 Feb; 8(2):e2626. PubMed ID: 28230855
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
Che L; Chi W; Qiao Y; Zhang J; Song X; Liu Y; Li L; Jia J; Pilo MG; Wang J; Cigliano A; Ma Z; Kuang W; Tang Z; Zhang Z; Shui G; Ribback S; Dombrowski F; Evert M; Pascale RM; Cossu C; Pes GM; Osborne TF; Calvisi DF; Chen X; Chen L
Gut; 2020 Jan; 69(1):177-186. PubMed ID: 30954949
[TBL] [Abstract][Full Text] [Related]
15. Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway.
Zhou S; Xu H; Tang Q; Xia H; Bi F
Mol Cancer Ther; 2020 Jan; 19(1):135-146. PubMed ID: 31554653
[TBL] [Abstract][Full Text] [Related]
16. Estrogen induces LCAT to maintain cholesterol homeostasis and suppress hepatocellular carcinoma development.
He W; Wang M; Zhang X; Wang Y; Zhao D; Li W; Lei F; Peng M; Zhang Z; Yuan Y; Huang Z
Cancer Res; 2024 May; ():. PubMed ID: 38718297
[TBL] [Abstract][Full Text] [Related]
17. LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway.
Xing Y; Liu Y; Qi Z; Liu Z; Wang X; Zhang H
Cell Mol Biol Lett; 2021 Nov; 26(1):49. PubMed ID: 34837962
[TBL] [Abstract][Full Text] [Related]
18. circ_HMGCS1 modulates hepatocellular carcinoma chemoresistance via miR-338-5p/IL-7 pathway.
Zhang S; Ma J; Yu T; Song Z; Lau WY; Zha Y
J Cell Mol Med; 2024 Mar; 28(6):e18137. PubMed ID: 38445791
[TBL] [Abstract][Full Text] [Related]
19. Maprotiline Suppresses Cholesterol Biosynthesis and Hepatocellular Carcinoma Progression Through Direct Targeting of CRABP1.
Zheng C; Zhu Y; Liu Q; Luo T; Xu W
Front Pharmacol; 2021; 12():689767. PubMed ID: 34093212
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting cholesterol de novo synthesis promotes hepatocellular carcinoma progression by upregulating prostaglandin E synthase 2-mediated arachidonic acid metabolism under high fatty acid conditions.
Zhao Z; Liu X; Xiang Y; Hou Z; He K; Zhong G; Hu J; Cai D; Liu Y; Ren J; Gong J; Zhao L
Cancer Sci; 2024 Feb; 115(2):477-489. PubMed ID: 38081591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
